August 4, 2015 (Shareholders Foundation) - An investigation was launched on behalf of investors of Bellerophon Therapeutics Inc (NASDAQ:BLPH) shares over potential securities laws violations by Bellerophon Therapeutics and certain of its directors and officers in connection certain financial statements.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Bellerophon Therapeutics Inc (NASDAQ:BLPH) concerning whether a series of statements by Bellerophon Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Bellerophon Therapeutics Inc reported that its Net Loss declined from $62 million in 2013 to $59.67 million in 2014. Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) traded as high as $12.00 per share in February 2015.

On July 27, 2015, Bellerophon Therapeutics Inc announced top-line results from its PRESERVATION I clinical trial for Bioabsorbable Cardiac Matrix (BCM), an investigational, implantable medical device being studied for the prevention of heart failure following an acute myocardial infarction (AMI), commonly known as a heart attack.

Bellerophon Therapeutics Inc said that topline results of the 303-patient, randomized, double-blind, placebo-controlled study, enrolled at 61 clinical sites in Australia, Europe, Israel and North America, showed no statistically significant treatment differences between patients treated with BCM and patients treated with placebo for both the primary and the secondary endpoints.

Shares of Bellerophon Therapeutics Inc (NASDAQ:BLPH) dropped on July 27, 2015, to as low as $2.75 per share.